Lv12
70 积分 2025-05-13 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
22小时前
已完结
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
22小时前
已完结
Cancer burden and control in China: landscape, trends and challenges
1天前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
1天前
已完结
T cell engagers in autoimmune diseases
1天前
已完结
Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions
7天前
已完结
Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
8天前
已完结
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
10天前
已完结
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
14天前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
15天前
已完结
皖公网安备34019202002308
